title: BMP-7 versus BMP-2 for the treatment of long bone nonunion.
abstract: The authors compared the results of treating nonunion with either bone morphogenetic protein (BMP)-7 or BMP-2. Between 2001 and 2009, 214 limb segments were treated for nonunion with either BMP-7 or BMP-2 at the authors' institution. Sixty-three subjects received 76 units of BMP-7. Radiographic healing occurred in 70% of limb segments at an average of 30 weeks after surgery, and 75% of limb segments were weight bearing at an average of 23 weeks after surgery. In 15.8%, persistent nonunion necessitated additional surgery. Average follow-up was 32 months. One hundred twelve subjects received 138 units of BMP-2. Radiographic healing occurred in 93% of limb segments at an average of 19 weeks after surgery, and 88% were weight bearing at an average of 15 weeks after surgery. In 6.25%, persistent nonunion necessitated additional surgery. Average follow-up was 17 months. Several significant differences were observed. Patients in both BMP-7 and BMP-2 groups were able to fully weight bear at an average of 23 and 15 weeks, respectively (P<.001). Further, both BMP-7 and BMP-2 groups healed at an average of 30 and 19 weeks, respectively (P<.001). Additionally, healing occurred in more limb segments in the BMP-2 group (93%) than in the BMP-7 group (70%) (P<.001). No difference in the complication rate was seen between groups. Patients who received BMP-2 for the treatment of nonunion had a higher rate of radiographic healing, achieved radiographic healing more quickly, and were able to bear weight sooner than those who underwent treatment with BMP-7.
authors.forename: Janet D
authors.initials: JD
authors.lastname: Conway
authors.forename: Lior
authors.initials: L
authors.lastname: Shabtai
authors.forename: Alexandra
authors.initials: A
authors.lastname: Bauernschub
authors.forename: Stacy C
authors.initials: SC
authors.lastname: Specht
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D055396:Bone Morphogenetic Protein 2 / Q000627:therapeutic use*; D055419:Bone Morphogenetic Protein 7 / Q000627:therapeutic use*; D002648:Child; D002675:Child, Preschool; D005260:Female; D005264:Femoral Fractures / Q000188:drug therapy* / Q000503:physiopathology; D017102:Fracture Healing / Q000187:drug effects; D005599:Fractures, Ununited / Q000188:drug therapy* / Q000503:physiopathology; D006801:Humans; D006810:Humeral Fractures / Q000188:drug therapy* / Q000503:physiopathology; D008297:Male; D008875:Middle Aged; D013978:Tibial Fractures / Q000188:drug therapy* / Q000503:physiopathology; D016474:Weight-Bearing; D055815:Young Adult
chemical_list: D055396:Bone Morphogenetic Protein 2; D055419:Bone Morphogenetic Protein 7